COMMUNIQUÉS West-GlobeNewswire
-
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11/03/2026 -
Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
11/03/2026 -
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026 -
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea
11/03/2026 -
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
11/03/2026 -
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026 -
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026 -
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
11/03/2026 -
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026 -
La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2
11/03/2026 -
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
11/03/2026 -
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026 -
NurExone Announces Corporate Updates
11/03/2026 -
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026 -
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/03/2026 -
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
11/03/2026 -
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026 -
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
11/03/2026 -
AiM Medical Robotics adds surgical robotics pioneer, Dr. Yulun Wang, to its world-class Board
11/03/2026
Pages